Home › Funds › Woodline Partners LP › PTGX

Woodline Partners LP position in PTGX

PROTAGONIST THERAPEUTICS INC · Health Care

Woodline Partners LP reported holding 1,414,173 shares of PTGX (PROTAGONIST THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$173.3M, representing 0.54% of its reported portfolio and ranking #24 among its reported holdings. Woodline Partners LP has disclosed PTGX holdings in 10 of the last 10 reported quarters, going back to Q1 2024.

Latest position (Q2 2026)1.41M sh
Reported value held$173.35M
Portfolio Weight0.54%
First reportedQ1 2024
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Woodline Partners LP's PTGX position evolved

Woodline Partners LP first disclosed a stake in PTGX in Q1 2024 at 636,956 shares (US$18.4M). The position peaked in Q2 2026 at 1,414,173 shares, worth US$173.3M. Across 10 filings, Woodline Partners LP increased the stake 5 time(s), trimmed it 2 time(s) and left it unchanged 2 time(s). The most recent filing (Q2 2026) shows 1,414,173 shares valued at US$173.3M. Notable position changes include a 43% trim in Q3 2024 (shares fell 14% over the following quarter), a 54% increase in Q1 2025 (shares rose 14% over the following quarter), a 52% increase in Q3 2025 (shares rose 31% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2024 636.96K $18.43M New
Q2 2024 822.17K $28.49M Add
Q3 2024 466.52K $20.99M Reduce
Q4 2024 582.33K $22.48M Add
Q1 2025 897.70K $43.41M Add
Q2 2025 946.88K $52.33M Add
Q3 2025 1.44M $95.54M Add
Q4 2025 1.41M $123.04M Reduce
Q1 2026 1.41M $149.05M Hold
Q2 2026 1.41M $173.35M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About PTGX and 13F data

PTGX (PROTAGONIST THERAPEUTICS INC) is a Health Care company. 48 other funds we track also report a position in PTGX — the largest reported positions include Farallon Capital Management (US$778.2M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$778.2M), RTW INVESTMENTS, LP (US$620.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding PTGX

All PTGX fund holders →

FAQ

How long has Woodline Partners LP held PTGX?

Woodline Partners LP has disclosed PTGX holdings in 10 of the last 10 reported quarters, going back to Q1 2024.

What is Woodline Partners LP's current position in PTGX?

As of Q2 2026, Woodline Partners LP holds 1.41M shares of PTGX (PROTAGONIST THERAPEUTICS INC), valued at $173.35M, representing 0.54% of its reported portfolio and ranking #24.

Has Woodline Partners LP been buying or selling PTGX?

In the latest 13F filing (Q2 2026), Woodline Partners LP held unchanged its position in PTGX. The position peaked in Q2 2026 at 1.41M shares.

Which other funds hold PTGX?

Other major institutional holders of PTGX include Farallon Capital Management, FARALLON CAPITAL MANAGEMENT, L.L.C., RTW INVESTMENTS, LP, among 48 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.